News articles about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a news impact score of 0.13 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.2001677274211 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of brokerages have weighed in on EDGE. BidaskClub raised Edge Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research upgraded Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, November 6th.
Shares of Edge Therapeutics (EDGE) opened at $10.77 on Friday. The company has a market capitalization of $343.77, a price-to-earnings ratio of -6.90 and a beta of 2.52. The company has a current ratio of 8.34, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. Edge Therapeutics has a twelve month low of $7.30 and a twelve month high of $12.20.
In other news, insider Brian A. Leuthner sold 7,500 shares of the company’s stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $10.91, for a total transaction of $81,825.00. Following the completion of the sale, the insider now directly owns 102,736 shares in the company, valued at approximately $1,120,849.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian A. Leuthner sold 5,000 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $10.11, for a total value of $50,550.00. Following the sale, the insider now owns 87,736 shares of the company’s stock, valued at $887,010.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,361 shares of company stock valued at $292,035. Insiders own 36.19% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Edge Therapeutics (EDGE) Stock Price” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.com-unik.info/2018/01/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-edge-therapeutics-edge-stock-price.html.
About Edge Therapeutics
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
What are top analysts saying about Edge Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edge Therapeutics and related companies.